Prednisolone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Prednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisolone is a systemic glucocorticoid with broad anti-inflammatory and immunosuppressive activity; no specific original indication or Taiwan marketing record is documented in this evidence pack. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 clinical trials and 20 publications returned by evidence search, though only a limited subset directly and specifically supports corticosteroid use in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (no original_indications or Taiwan license data available) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for prednisolone is not available in this evidence pack, and no original approved indication is recorded (Taiwan regulatory status: Not Marketed, 0 registrations). Based on general pharmacological knowledge, prednisolone is a systemic corticosteroid with broad anti-inflammatory and immunosuppressive activity, consistent with its established use across a wide range of autoimmune and inflammatory conditions.
Alopecia areata (AA) is a T-cell-mediated autoimmune attack on the hair follicle. Corticosteroids (including prednisolone/methylprednisolone) suppress the perifollicular lymphocytic infiltrate through broad immunosuppressive and anti-inflammatory action, and are already widely used clinically — particularly as pulse therapy — for moderate-to-severe AA. This gives the TxGNN prediction a plausible mechanistic basis.
However, it is worth noting that most large, contemporary Phase 2/3 RCTs identified for AA target newer-mechanism agents such as the JAK inhibitor baricitinib, rather than prednisolone itself. The direct evidence base for prednisolone specifically consists mainly of smaller cohort studies, one Phase 4 trial, and one older placebo-controlled trial, which is reflected in the moderate (L2) evidence level.
Clinical Trial Evidence
The evidence search returned 18 trials for “Prednisolone + Alopecia Areata,” but most (SLE trials of JAK inhibitors/biologics, an occipital nerve block technique study, a prostate cancer trial) are not specific to prednisolone in AA and were excluded as low relevance. The trials below were graded most relevant:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone (higher dose, more frequent pulses) in severe therapy-resistant AA; systemic pulse glucocorticoids are effective in widespread AA but not in totalis/universalis/ophiasic subtypes. |
| NCT01017510 | N/A | Unknown | 20 | Compared Dermojet (needle-free) vs. standard syringe for intralesional corticosteroid injection in AA; supports corticosteroid injection as a conventional AA treatment. |
| NCT07101471 | N/A | Completed | 296 | Observational safety/effectiveness study of tofacitinib in alopecia; participants received tofacitinib with or without adjuvant prednisolone. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15692475 | 2005 | RCT | J Am Acad Dermatol | First randomized, placebo-controlled trial of oral pulse prednisolone therapy in AA. |
| 37870096 | 2023 | Review (Cochrane) | Cochrane Database Syst Rev | Network meta-analysis of AA treatments, including immunosuppressants such as corticosteroids. |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Review of corticosteroid pulse therapy efficacy, relapse rates, side effects, and prognostic factors in AA. |
| 30191561 | 2019 | Review | Australas J Dermatol | Systematic review of systemic treatments (including corticosteroids) for AA, totalis, and universalis. |
| 41243342 | 2025 | Review | J Dermatolog Treat | Dexamethasone oral mini-pulse achieved durable remission in severe AA when JAK inhibitors were not an option. |
| 35986630 | 2022 | Cohort | Dermatol Ther | Retrospective comparison of methylprednisolone alone vs. methylprednisolone + methotrexate in extensive AA. |
| 28140540 | 2017 | Cohort | J Dtsch Dermatol Ges | Sequential high- then low-dose systemic corticosteroid therapy in severe childhood AA; good initial response, relapse common after discontinuation. |
| 21572877 | 2009 | Cohort | Dermatoendocrinol | Medium-dose prednisolone pulse therapy effective in early-stage AA, but significant side effects led to treatment discontinuation in some patients. |
| 22426909 | 2012 | Case Series | Saudi Med J | Oral mega-pulse methylprednisolone in severe therapy-resistant AA (literature counterpart to trial NCT01167946). |
| 30294905 | 2019 | Mechanistic | J Cosmet Dermatol | Changes in serum/tissue TNF-α levels proposed as a possible mechanism of oral pulse steroid action in AA. |
India Market Information
No marketing authorizations for Prednisolone are on record in this dataset — status is Not Marketed with 0 registrations.
Safety Considerations
Drug Interactions: The DDI database records 753 total documented interactions for Prednisolone (source: DDInter). Of the 20-item sample returned, most are Moderate-severity (e.g., NSAIDs such as ibuprofen/ketorolac, beta-agonists, acarbose, acetazolamide, nifedipine, ethinylestradiol, various biologics); Adalimumab is flagged as a Major-level interaction. Given the size of the full interaction set, a complete review against any concomitant medication list is recommended before clinical use.
No TFDA label warnings or contraindications are available in this evidence pack for other safety domains — please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Clinical experience with corticosteroid pulse therapy (including a Phase 4 trial and an older placebo-controlled RCT) supports prednisolone/methylprednisolone activity in moderate-to-severe AA, but most large contemporary RCTs in this space target newer JAK-inhibitor agents rather than prednisolone itself, and no Taiwan-specific regulatory or MOA data are currently available — placing this candidate at Evidence Level L2 / Decision Stage S2.
To proceed, the following is needed:
- TFDA-approved label / package insert (warnings and contraindications) — currently a Blocking gap that prevents initial safety assessment (S1)
- Confirmed mechanism-of-action data via DrugBank API (High-severity gap)
- Documentation of prednisolone’s original approved indication(s) and Taiwan market/license status
- Route and dosing compatibility assessment specific to AA (currently unassessed/pending)
- Full 753-entry DDI review for indication-relevant contraindicated combinations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.